Search results for "embolism"

showing 10 items of 457 documents

International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists

2019

Introduction and objectives: Heart failure patients with nonvalvular atrial fibrillation (NVAF) on treatment with vitamin K antagonists (VKA) often have suboptimal international normalized ratio (INR) values. Our aim was to evaluate the association between INR values at admission due to acute heart failure and mortality risk during follow-up. Methods: In this observational study, we retrospectively assessed INR on admission in 1137 consecutive patients with acute heart failure and NVAF who were receiving VKA treatment. INR was categorized into optimal values (INR = 2-3, n = 210), subtherapeutic (INR 3, n = 267). Because INR did not meet the proportional hazards assumption for mortality, res…

Maleendocrine systemmedicine.medical_specialtyTime FactorsVitamin KHeart failure030204 cardiovascular system & hematologyVitamin kRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeCause of DeathThromboembolismhealth services administrationMean Survival TimeInternal medicineAtrial FibrillationmedicineHumansheterocyclic compoundsInternational Normalized Ratiocardiovascular diseasesInternational normalized ratioNormal rangeAgedRetrospective StudiesHeart Failurebusiness.industryIncidencefungiAnticoagulantsAtrial fibrillationGeneral MedicinePrognosismedicine.diseaseAtrial fibrillationSurvival RateSpainHeart failureAcute DiseaseCardiologyFemaleObservational studybusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct

'Pulmonary thrombosis in situ': risk factors, clinic characteristics and long-term evolution.

2020

: Pulmonary embolism typically occurs from deep venous thrombosis (DVT). However, not always a DVT can be identified, and 'in situ' generation of pulmonary embolism has been considered, referred to in the literature as 'De novo pulmonary embolism' (DNPE). The objective of the study is to assess risk factors, comorbidities, clinic characteristics and long-term evolution of patients with pulmonary embolism in the absence of an identified source. Retrospective study of 280 patients with pulmonary embolism, 190 pulmonary embolisms with DVT group and 90 (32%) pulmonary embolism without DVT (DNPE group), admitted to an Internal Medicine Department of a tertiary hospital from January 2012 to Decem…

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk-TakingRisk FactorsInternal medicinemedicineHumansAgedRetrospective StudiesCOPDbusiness.industryRespiratory infectionRetrospective cohort studyHematologyGeneral MedicineOdds ratiomedicine.diseasePulmonary embolismVenous thrombosisEmbolismHeart failureFemalebusinessPulmonary Embolism030215 immunologyBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Impact of concomitant deep or superficial venous thrombosis of the legs on survival of patients with pulmonary embolism

2019

Pulmonary embolism (PE) is a frequent cause of death and morbidity. A few studies suggest that clot burden in pulmonary artery bed is related to PE patients' survival, but the impact of concomitant deep venous thrombosis and/or thrombophlebitis (DVT) on short-term survival of PE patients remains unclear. Thus, we aimed to investigate the impact of DVT on adverse outcomes in PE patients.Patients of the nationwide inpatient sample with PE (ICD-code I26) were stratified for DVT (ICD-code I80) and compared for patient characteristics, risk stratification markers, treatments and outcomes. Impact of concomitant DVT on adverse in-hospital outcomes was tested.Overall, 346,586 PE patients (53.3% fem…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicine.arterymedicineHumanscardiovascular diseases030212 general & internal medicineCause of deathVenous ThrombosisInpatientsLegbusiness.industryCancermedicine.diseasePulmonary embolismVenous thrombosisConcomitantPulmonary arterySuperficial venous thrombosisFemalePulmonary EmbolismCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Management of bleeding in patients hospitalized in the intensive cardiac care unit: expert opinion of the Association of Intensive Cardiac Care and S…

2019

ABSTRACT Nowadays, the intensive cardiac care unit (ICCU) provides care for patients with acute coronary syndrome, acute and exacerbated chronic heart failure, cardiogenic shock, sudden cardiac arrest, electrical storm, as well as with indications for urgent cardiac surgical treatment. Most of these patients require the use of 1, 2, or frequently even 3 drugs that act on the blood coagulation pathway. While antithrombotic drugs prevent thromboembolic events, they are associated with a higher risk of bleeding. In this population of patients, bleeding may often have a worse impact on prognosis than the primary disease. In this expert opinion of the Association of Intensive Cardiac Care, we pr…

Malemedicine.medical_specialtyAcute coronary syndromePopulationCardiologyHemorrhagePharmacotherapyFibrinolytic AgentsRisk FactorsThromboembolismAntithromboticmedicineHumansIn patientCardiac Surgical ProceduresIntensive care medicineeducationSocieties MedicalAgedAged 80 and overeducation.field_of_studybusiness.industryCardiogenic shockDisease ManagementSudden cardiac arrestmedicine.diseaseIntensive Care UnitsHeart failureFemalePolandmedicine.symptomCardiology and Cardiovascular MedicinebusinessKardiologia polska
researchProduct

International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs.

2017

We sought to determine the test characteristics of an automated INNOVANCE D-dimer assay for the exclusion of pulmonary embolism (PE) and deep venous thrombosis (DVT) in emergency department (ED) patients using standard and age-adjusted cut-offs.Cross-sectional, international, multicenter study of consecutive patients with suspected DVT or PE in 24 centers (18 USA, 6 Europe). Evaluated patients had low or intermediate Wells PE or DVT scores. For the standard cut-off, a D-dimer result500 ng/ml was negative. For the age adjusted cut-off, we used the formula: Age (years) ∗ 10. The diagnostic standard was imaging demonstrating PE or DVT within 3 months. We calculated test characteristics using s…

Malemedicine.medical_specialtyAge adjustment030204 cardiovascular system & hematologyD-dimer assayFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicinebusiness.industryAge FactorsHematologyEmergency departmentVenous ThromboembolismMiddle Agedmedicine.diseasePulmonary embolismVenous thrombosisCross-Sectional StudiesMulticenter studyDecreased SensitivityBiological AssayFemalebusinessVenous thromboembolismThrombosis research
researchProduct

Left atrial thrombi despite anticoagulant and antiplatelet therapy

1994

To investigate risk factors for embolization in patients with echocardiographically detected left atrial thrombi and to evaluate thrombus development, we examined 29 patients with transesophageal and transthoracic echocardiography at two points during a follow-up of 18 months. We compared patients with a history of possible arterial embolization (n = 13) with those without (n = 16) in regard to age, gender, left atrial dilatation, localization of the thrombus in the left atrial cavity, spontaneous echo contrast, and atrial fibrillation. Eight patients were treated with aspirin, 20 with phenprocoumon. Only left atrial spontaneous contrast was associated with thromboembolism (10/15 patients w…

Malemedicine.medical_specialtyArterial embolismHeart Diseasesmedicine.drug_classmedicine.medical_treatmentEmbolismRisk FactorsInternal medicineAtrial FibrillationmedicineHumansMitral Valve StenosisHeart Atriacardiovascular diseasesEmbolizationThrombusAgedPeripheral Vascular DiseasesAspirinHeparinbusiness.industryArterial EmbolizationAnticoagulantThrombosisAtrial fibrillationGeneral MedicineIntracranial Embolism and ThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEmbolismEchocardiographyPhenprocoumoncardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealDilatation PathologicFollow-Up Studiescirculatory and respiratory physiologyClinical Cardiology
researchProduct

Venous thromboembolism in patients hospitalized for hip joint replacement surgery

2020

Venous thromboembolism (VTE) is a potentially life-threatening disease. Major transient risk factors include trauma, surgery, and immobilization. Patients undergoing hip joint replacement (HJR) are characterized by a high risk of postoperative VTE, but data on the time trends of VTE rates in this population are sparse.In an analysis of the German nationwide inpatient sample, we included all hospitalizations for elective primary HJR in Germany from 2005 to 2016. Time trends of the surgical procedure, overall death rates, and VTE rates were analysed, and predictors of VTE identified.Overall, 1,885,839 inpatients with elective primary HJR (59.1% women, 51.4% ≥70 years) were included in the ana…

Malemedicine.medical_specialtyArthroplasty Replacement HipPopulation2720 Hematology610 Medicine & healthDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsHip replacementGermanymedicineHumanscardiovascular diseasesHospital Mortalityeducationeducation.field_of_studybusiness.industryMortality rate10031 Clinic for AngiologyCancerPerioperativeVenous ThromboembolismHematologyequipment and suppliesmedicine.diseaseSurgeryPulmonary embolismHospitalization030220 oncology & carcinogenesisFemalebusinessVenous thromboembolism
researchProduct

Pathogenesis and prophylaxis of circulatory reactions during total hip replacement

1993

Circulatory reactions such as a drop in blood pressure, bradycardia, cardiac arrest, and even intraoperative death after insertion of the stem are well known events during total hip replacement. The present paper reports bone marrow intravasation after rise of intramedullary pressure in the femoral cavity during insertion of hip prostheses, demonstrated by intraoperative transesophageal echocardiography. In an animal study, the ultrasound echoes were identified as "mixed emboli" consisting of a core of bone marrow surrounded by thrombus. These results suggested the use of an intramedullary plug to restrict the intravasation of bone marrow. A trial was undertaken in 60 total hip replacement …

Malemedicine.medical_specialtyBlood PressureEmbolism FatVena Cava InferiorOsteoarthritis Hiplaw.inventionIntramedullary rodFemoral headBone MarrowlawAnimalsHumansMedicineOrthopedics and Sports MedicineFemurThrombusFat embolismIntraoperative ComplicationsAgedUltrasonographyAged 80 and overHip surgerySheepbusiness.industryHemodynamicsGeneral MedicineMiddle Agedmedicine.diseaseFemoral Neck FracturesSurgerymedicine.anatomical_structureOrthopedic surgeryFemaleSurgeryHip ProsthesisRadiologyBone marrowbusinessCancellous boneArchives of Orthopaedic and Trauma Surgery
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct